Traditional cytotoxic cancer chemotherapies kill rapidly dividing cancer and normal cells in an indiscriminate manner, leading to significant toxicity in patients. in response to this limitation, a number of targeted therapies were developed to be more selective, including monoclonal antibody-based therapies. For certain cancers, antibodies alone are not sufficiently effective to achieve meaningful clinical benefit. This limitation has led to the development of a new class of agents called antibody drug conjugates, or ADCs. ADCs are comprised of a monoclonal antibody, which is used to target the specific cancer, attached via a linker system to a cell-killing drug.
We believe our SMDC platform represents a novel approach, comparable to ADCs in its ability to deliver highly active drug payloads in a targeted manner, but also with a number of potential advantages:
- Small size to better penetrate solid tumors
- Rapid clearance for reduced toxicity
- Companion imaging diagnostics for targeted therapy
- Cost-effective and simple to manufacture